Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Lung Neoplasms 6Carcinoma, Non-Small-Cell Lung 5Multiple Myeloma 2Lymphoma 2Hematologic Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Melanoma 1Glioma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Brain Neoplasms 1Advanced Lung Non-Squamous Non-Small Cell Carcinoma 1Adenocarcinoma of Lung 1

Interventions

osimertinib 1navitoclax 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Advanced Lung Non-Squamous Non-Small Cell Carcinoma × osimertinib × Clear all
NCT02520778 2024-08-21

Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 1 Completed
27 enrolled

Advanced Lung Non-Squamous Non-Small Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡